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Abstract
Soft tissue sarcomas comprise a heterogeneous group of aggressive tumors that have a relatively poor prognosis. Although
conventional therapeutic regimens can effectively cytoreduce the overall tumor mass, they fail to consistently achieve a
curative outcome. Alternative gene-based  approaches  that counteract the underlying neoplastic process by  eliminating
the clonal aberrations that potentiate malignant behavior have been proposed. As compared to the accumulation of gene
alterations associated with epithelial carcinomas, sarcomas are frequently characterized by the unique presence of a single
chromosomal translocation in each histological subtype. Similar to the Philadelphia chromosome associated with CML,
these clonal abnormalities result in the fusion of two independent unrelated genes to generate a unique chimeric protein
that displays aberrant activity believed to initiate cellular transformation. Secondary gene mutations may provide an addi-
tional growth advantage that further contributes to malignant progression. The recent clinical success of the tyrosine kinase
inhibitor, STI571, suggests that therapeutic approaches specifically directed against essential survival factors in sarcoma cells
may be effective. This review summarizes published approaches targeting a specific molecular mechanism associated with
sarcomagenesis. The strategy and significance of published translational studies in six distinct areas are presented. These
include: (1) the disruption of chimeric transcription factor activity; (2) inhibition of growth stimulatory post-translational
modifications; (3) restoration of tumor suppressor function; (4) interference with angiogenesis; (5) induction of apoptotic
pathways; and (6) introduction of toxic gene products. The potential for improving outcomes in sarcoma patients and the
conceptual obstacles to be overcome are discussed.
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Introduction
Sarcomas  are  non-epithelial  tumors  derived  from
embryonic mesoderm or  neuroectoderm, and may
arise from the peripheral nervous system, cartilage,
bone, muscle, adipose tissue, vascular components
and various fibrous structures of the body. Approxi-
mately  2600  new  cases  of  bone  and  cartilaginous
tumors are diagnosed each year in the United States
and are commonly distinguished from soft tissue sar-
comas that account for 5200 new cases each year.1–5
Since there are  multiple distinctive subtypes, each
category of tumor is relatively uncommon compared
to epithelial tumors such as breast or lung cancer.
None-the-less, important lessons have been learned
by  studying  these  relatively  rare  neoplasms.  Over
the past two decades, advances in medical research
have  appreciably  expanded  our  understanding  of
sarcoma biology. As compared to the accumulation
of mutations associated with epithelial carcinomas,1
cytogenetic studies of sarcomas have revealed struc-
tural abnormalities associated with specific histologi-
cal  tumor  types  and  aided  the  development  of
sensitive  diagnostic  techniques.2,6,7  Characteristic
gene  aberrations  found  in  sarcomas  are  shown  in
Table  1.  Balanced  chromosomal  translocations
frequently juxtapose two unrelated genes to form a
novel  tumor-associated  transcript  (Fig.  1).  Com-
monly, the unrelated genes are transcription factors
such as TLS (translocated in liposarcoma) which is
fused  to  CHOP  (C/EBP  homology  protein)  in
myxoid/round  cell  liposarcoma  with  the  t(12;16)
(q13;p11)  translocation.8  Characteristic  chromo-
somal  changes  have  proved  useful  in  establishing
specific tumor subtypes with prognostic significance,
such as t(X;18)(p11.2;q11.2) that joins SYT (syno-
vial sarcoma translocation protein) to either SSX1 or
SSX2 (synovial sarcoma X chromosome breakpoint
protein 1 or 2) in synovial sarcoma.9 Tumors with
the SYT/SSX1  fusion  demonstrate  a  significantly28 R. J. Olsen et al.
poorer prognosis than the STY/SSX2 gene fusion.10
Alternatively, sporadic mutations occur that second-
arily influence neoplastic development by providing
additional growth advantages.11 In combination with
biochemical  analyses,  these  studies  have  provided
significant  insight  into  the  molecular  nature  of
sarcoma  cells  and  their  mechanism for  neoplastic
transformation.12,13 It is generally believed that these
characteristic chromosomal abnormalities represent
the initiating genetic event and possibly constitute the
Fig. 1. Schematic representation of modular gene components involved with chromosomal translocations. In this example, both genes
are transcription factors and contain multiple components including a regulatory domain that may be silent or activated by specific
signals, a DNA-binding domain and a dimerization domain. Exchange of genetic material at the breakpoint shown (arrow) results
in a unique chimeric transcript that contains domains from both parental components. Due to this arrangement, the fusion protein may
be over-expressed in tumor cells and demonstrate dysregulated activity. Although balanced translocations create two novel gene products,
only one typically results in a functional protein associated with sarcomagenesis.
Table 1. Genetic mechanisms characteristic of human sarcoma
Tumor type Molecular alteration Involved genes
Alveolar t(2;13)(q35;q14) PAX3/FKHR
Rhabdomyosarcoma t(1;13)(p36;q14) PAX7/FKHR
Clear cell sarcoma t(12;22)(q13;q12) EWS/ATF1
Congenital fibrosarcoma t(12;15)(p13;q25) TEL/NTRK3
Dermatofibrosarcoma t(17;22)(q22;q13) COL1A1/PDGFß
DSRCT t(11;22)(p13;q12) EWS/WT1
Extraskeletal myxoid t(9;22)(q22;q12) EWS/TEC
Chondrosarcoma t(9;17)(q22;q12) TAF2N/TEC
Embryonal Trisomy 2 Unknown
Rhabdomyosarcoma Trisomy 8 Unknown
Epithelioid sarcoma LOH 22q Unknown
Ewing’s sarcoma t(11;22)(q24;q12) EWS/FLI1
t(21;22)(q22;q12) EWS/ERG
t(7;22)(p22;q12) EWS/ETV1
t(2;22)(q33;q12) EWS/FEV
t(17;22)(q12;q12)  EWS/E1AF
Trisomy 8 N/A
Trisomy 12 N/A
Fibrosarcoma t(12;15)(p13;q25) ETV6/NTRK3
GI stromal tumor 4q11–21 mutation c-KIT
Hemangiopericytoma t(12;19)(q13;q13) Unknown
Leiomyosarcoma t(12;14) Unknown
Malignant fibrous histiocytoma Complex karyotype Unknown
Malignant rhabdoid tumor del 22(q11.2) Unknown
Myxoid/round cell t(12;16)(q13;p11) TLS/CHOP
Liposarcoma t(12;22)(q13;q12) EWS/CHOP
Synovial sarcoma t(X;18)(p11;q11) SYT/SSX1
t(X;18)(p11;q11) SYT/SSX2Molecular approaches to sarcoma therapy 29
underlying  molecular  mechanism  for  malignant
proliferation.  However,  new  treatment  modalities
exploiting this knowledge have only recently begun to
appear.
The therapeutic management of soft tissue sarco-
mas represents a difficult clinical challenge. Aggres-
sive surgical intervention provides the only effective
means for a successful cure; however, many tumors
are either too large or are located within vital struc-
tures and deep tissues that prevent their total resec-
tion.5,14–19 Nearly 50% of all sarcomas recur within
2 years of treatment,20 fewer than 25% of patients
presenting  with  metastatic  disease  at  diagnosis
survive  for  5  years21,22  and  the  5-year  mortality
rate following surgical failure is 91%.23,24 The 1997
Sarcoma  Meta-Analysis  Collaborative  Report  on
1568  patients  in  14  trials  evaluating  the  potential
impact of adjuvant chemotherapy agents clearly dem-
onstrated the limitations of conventional therapy.188
Local control and event-free survival for the  1568
enrolled  patients  was  significantly  improved  by
doxorubicin-based  chemotherapy  regimens;  how-
ever, no benefits to overall survival were observed.
Similarly, Gortzak et al. recently published the results
of a randomized trial comparing neoadjuvant doxo-
rubicin  and  ifosfamide  plus  surgery  to  surgery
alone.189 One hundred and thirty-four patients with
high-risk  sarcomas  were  evaluated  with  a  median
follow-up  of  7.3  years.  The  5-year  disease-free
survival and overall survival rates were similar in both
groups. Disease-free survival was 56% in the chemo-
therapy plus surgery group compared to 52% in the
surgery alone group, and the overall survival rates
were 65  and 64%,  respectively. Collectively, these
studies  suggest  that  adjuvant  and/or  neoadjuvant
chemotherapy  agents  fail  to  significantly  improve
clinical outcomes and should not be routinely recom-
mended  for  sarcoma  patients.  Thus,  laboratory
research  directed  towards  the  development  of
improved therapeutic options is clearly needed. 
The  goal  of  molecular  therapeutics  is  to  treat
specific human disease with biomolecules engineered
to operate at the genetic level. The underlying belief
is  that  pathological  processes can  be  alleviated  by
either altering gene expression, manipulating cellular
activities  or  enhancing  immune  function.  The
embryological  relationship  between  tumors  arising
from mesenchymal tissues including both hematolog-
ical  malignancies  and  sarcomas,  may  hold  special
significance. By targeting a specific neoplastic process
leading  to  chronic  myelogenous  leukemia  (CML)
and sarcoma, phosphokinase inhibitors have recently
demonstrated the feasibility of using pharmacological
approaches  based  on  molecular  mechanisms  for
cancer  therapy.3  Studies  have  been  expanded  to
include targeting  of  a  second mesenchymal tumor
type,  gastrointestinal  stromal  tumor  (GIST),  with
a tumor  specific  c-KIT  (CD117)  mutation.27,28
However, this was not the first successful phamaco-
molecular approach as it had been preceeded by the
use of all trans-retinoic acid for the treatment of acute
promyelocytic leukemia (FAB M3) with a transloca-
tion of chromosomes 15 and 17.25,26 Both improved
response and outcome were achieved. 
The poor clinical outcome and unique molecular
basis of soft tissue sarcoma has stimulated numerous
investigations  into  its  susceptibility  for  gene-based
approaches. These emerging strategies seek to elimi-
nate tumor growth by utilizing molecular techniques
that target the characteristic gene properties defining
each tumor.2 By specifically targeting these genetic
changes  and  their  downstream  effects,  the  trans-
formed phenotype may be eliminated. This review
was initiated to identify published studies that have
targeted  mesenchymal  malignancies  arising  from
characteristic  chromosomal  aberrations  and  to
expand the number of targets appropriate for further
study.  A  number  of  promising  new  therapeutic
strategies for sarcoma were found and are reviewed
here, including disruption of chimeric transcription
factor activity, inhibition of growth stimulatory post-
translational  modifications,  restoration  of  tumor
suppressor  function,  blockade  of  angiogenesis,
induction of apoptotic pathways and introduction of
toxic  gene  products.  Molecular  approaches  using
cell-mediated immunity (CMI) and tumor vaccina-
tion  have  been  recently  reviewed  and  are  not
discussed here.14,29,30
Disruption of chimeric transcription factor 
activity
Cytogenetic studies have revealed a common theme
of nature in which balanced translocations generate
an aberrant transcription factor by joining the DNA
binding domain of one protein to the potent activa-
tion domain of a heterologous partner. Transcription
factors such as ATF1 and FLI1 are intimately associ-
ated  with  vital  cellular processes and the  effect  of
their incorporation into chimeric proteins is consist-
ent with their role in regulating cellular proliferation
and differentiation through control of gene expres-
sion.40,41 In tumor cells, the resulting fusion protein
tends  to  be  over-expressed,  displays  dysregulated
activity and demonstrates an increased transactiva-
tion  and  transforming  potential  in  comparison  to
its native counterparts.31–33,35 Transcription factors
are typically composed of multiple domains having
discreet functions such as DNA binding, dimeriza-
tion  or  regulation;  however,  the  combination  of
different domains from unrelated genes results in a
chimeric protein having properties distinct from its
individual  components (Fig.  1).  The  dysregulated
activation of target genes by fusion proteins has been
hypothesized  to  be  the  primary  initiating  event  in
sarcomagenesis.  For  example,  t(12;22)(q23;q12)
joins  EWS  (Ewing’s  sarcoma  protein)  to  FLI1
(Friend leukemia virus integration site 1 protein) in30 R. J. Olsen et al.
Ewing’s  sarcoma  of  bone  and  t(11;22)(q13;q12)
fuses EWS to ATF1 (activating transcription factor 1)
in clear cell sarcoma of tendon sheath and aponeuro-
ses.38 Alveolar rhabdomyosarcoma is characterized
by the translocation t(2;13)(q35;q14) that fuses the
PAX3 or PAX7 and FKHR (Forkhead) transcription
factors.39 The clonal nature of each genetic abnor-
mality and its consistent association with a specific
tumor type reinforces its apparent importance to the
underlying  neoplastic  program.  The  EWS/FLI1,
PAX/FKHR  and  TLS/CHOP  proteins  associated
with Ewing’s sarcoma, alveolar rhabdomyosarcoma
and  myxoid  liposarcoma,  respectively,  transform
murine  fibroblasts,  whereas  none  of  the  separate
genes composing the fusion are capable of transfor-
mation.33–36 Since expression of the chimeric tran-
scription factor may also play an important role in
the continued  progression  of  malignant  behavior,
disrupting its activity represents an attractive goal for
the design of new therapeutic agents.2,37
Ewing’s  sarcoma,  the  second  most  frequently
diagnosed childhood tumor of bone, represents an
optimal choice for targeting due to its relatively high
incidence and consistent association with the EWS/
FLI1 chimeric gene.42 Ouchida et al. first suggested
that fusion protein inhibition may be an appropriate
strategy to sarcoma management.43 Transfection of
antisense  plasmids  reduced  EWS/FLI1  expression
and significantly impaired its transforming activity in
murine fibroblasts. In addition, a 10-fold reduction
in anchorage-independent colony formation in soft
agar  was  observed,  tumorigenicity  in  surgically
prepared  mice  was  blunted  and  susceptibility  to
etoposide  and  actinomycin  D  was  increased.35,44
Tanaka and associates reported that antisense oligo-
nucleotides arrested the cell cycle at G0/G1, and the
level of in vitro and in vivo cytotoxicity was related to
antisense copy number.44 No effect was observed in
non-Ewing control cells. Kovar et al. demonstrated
that interference with wildtype EWS/FLI1 function
by a dominant negative EWS/FLI1 derivative lacking
the EWS transactivation domain effectively reduced
the mitotic activity of cultured Ewing’s sarcoma cells
but had no effect on neuroblastoma cells.45 Tumor
growth  was  restored  by  overexpression  of  the
wildtype EWS/FLI gene. Similar results have been
independently  reported  by  Toretsky  et  al.46  and
Lambert et al.47
Clear cell sarcoma, a rare tumor of tendon sheath
and aponeuroses, is characterized by the EWS/ATF1
fusion protein.48,49 Bosilevac and co-workers utilized
a  single-chain  variable  fragment  (scFv)  antibody
termed scFv41.4  to interfere with the ATF1 basic
DNA binding domain.50,51 They hypothesized that it
sterically  interfered  with  the  interaction  between
EWS/ATF1  and  cyclic-AMP  response  element
(CRE)  containing  promoters  to  inhibit  transcrip-
tional  activation.51  Intracellular  expression  of
scFv41.4 in the human clear cell sarcoma cell line,
SU-CCS-1, decreased endogenous EWS/ATF1 tran-
scriptional activity in luciferase reporter assays and
led to a significant induction of tumor cell death.31 At
10  days post-transfection by retroviral vector, only
10% of SU-CCS-1 cells remained viable in Trypan
blue dye exclusion assays and a 33% increase in the
number of apoptotic nuclei was measured by flow
cytometric analysis and TUNEL staining. No cyto-
toxic effect was observed in non-sarcoma control cell
lines. 
Alveolar rhabdomyosarcoma is the most common
soft  tissue  sarcoma  of  children under 15  years  of
age and  is  a  highly  aggressive  tumor arising  from
striated  muscle.52  Bernasconi  et  al.  demonstrated
that  treatment of alveolar rhabdomyosarcoma cells
with antisense oligonucleotides directed against the
mRNA translational start site inhibited fusion protein
expression and triggered an apoptotic cell death.53
Similarly, Fredericks et al. have studied the ability of
a  dominant  negative  PAX3/KRAB  transcriptional
repressor to block the transforming activity of PAX3/
FKHR.54 The inhibitory molecule was shown to suc-
cessfully compete with endogenous protein for PAX
binding sites, and its expression resulted in a loss of
cellular growth in low serum, reduced colony forma-
tion in soft agar and decreased tumor development in
SCID mice. 
Post-translational modifications
One of the most important regulatory mechanisms of
eukaryotic cells is the post-translational modification
of  proteins by  phosphorylation. In addition, other
post-translational  modifications, such as  glycosyla-
tion and prenylation, serve to control protein activity.
The functional modifications may induce conforma-
tional changes that alter intermolecular interactions,
stimulate downstream signal transduction cascades
or  dictate  subcellular  compartmentalization.55,56
Since transcription factors are commonly composed
of multiple domains with distinct activities, modifica-
tions of one component can allosterically influence
the activity of another component. Several important
studies  have  recently  suggested  that  post-transla-
tional  modification  of  sarcoma-associated  proteins
may  represent an  appropriate  target  for  molecular
intervention.
The  insulin-like growth  factor-1  receptor (IGF-
1R), a transmembrane tyrosine kinase that modulates
several tumor-associated activities including cellular
proliferation,  transformation  and  programmed cell
death, is thought to play an important role in many
different human sarcomas. It was recently observed
that N-linked glycosylation was required for IGF-1R
activity by stimulating transport to the cell surface. In
support of  the  concept that  blocking glycosylation
may convey an anti-tumorigenic effect, Girnita et al.
demonstrated  that  administration  of  tunicamycin
and  lovastatin  to  two  Ewing’s  sarcoma  cell  linesMolecular approaches to sarcoma therapy 31
resulted in the down-regulation of membrane-bound
IGF-1R and a rapid decrease in cellular survival.57
The growth arrest was later shown to be accompa-
nied by reduced expression of the EWS/FLI1 fusion
protein,58  increased  sensitization  to  doxorubicin
cytotoxicity  and  enhanced  susceptibility  to  exoge-
nous apoptotic stimuli.59
The tyrosine kinase inhibitor STI571 has shown
remarkable efficacy in treating chronic and acceler-
ated phase CML and other human neoplasms associ-
ated with phosphorylated proteins.60 Joensuu et al.
recently published the report of a patient with rapidly
progressive metastatic gastrointestinal stromal tumor
(GIST) responding to  STI571  treatment.27  These
mesenchymal  neoplasms  characteristically  demon-
strate  dominant  c-KIT  (CD117)  mutations  that
result in constitutive tyrosine kinase activity  which
may respond to inhibitors.28,61 Over 11 months of
treatment, the GIST patient underwent a significant
clinical response.27 No new lesions appeared, and the
primary tumor regressed by 52%. Also, six of 28 liver
metastases  disappeared.27  Similarly,  STI571  was
shown  to  significantly  reduce  the  tyrosine  kinase
activity of the COL1A1/PDGFß (collagen 1A1/plate-
let-derived growth factor ß) fusion protein associated
with  dermatofibrosarcoma  protuberans.62  Treat-
ment resulted in a loss of transforming activity in vitro
and a reduction of tumor cell growth in vivo. STI571
has been well-tolerated with infrequent side effects,63
and preliminary analysis demonstrated that 89% of
GI stromal tumors unresponsive to standard chemo-
therapy  showed  a  significant  clinical  response.64
Based on these impressive results, independent phase
I and phase II trials have been initiated for various
sarcomas.
The EWS  IQ  domain, a  conserved calmodulin-
binding motif that contains an internal protein kinase
C (PKC) phosphorylation site, is phosphorylated in
tumor  cells.65  Presence  of  the  IQ  domain  was
hypothesized to  regulate the transcriptional activa-
tion properties of EWS/ATF1 in clear cell sarcoma
and EWS/FLI1 in Ewing’s sarcoma. In vitro experi-
ments demonstrated that intracellular phosphoryla-
tion of serine266 in the EWS IQ domain significantly
enhanced the DNA-binding activity, transactivation
potential and nuclear localization of both chimeric
proteins.  Furthermore,  the  clinical  heterogeneity
observed in some Ewing’s sarcomas was theorized
to be  a  function of  post-translational modification
since multiple fusion transcript variations involving
different combinations of exons have been observed,
and  these  have  prognostic  significance.  Patients
diagnosed  with  a  Type  I  translocation  involving
EWS exons 1–7 and FLI1 exons 6–9 have a better
prognosis than  all others; whereas tumors demon-
strating a translocation that includes the additional
portion of EWS containing the IQ phosphorylation
domain  are  associated  with  a  considerably  poorer
outcome.66–68 
Restoration of tumor suppressor function
Homozygous loss or mutation of the Rb tumor sup-
pressor gene, such as occurs in retinoblastoma, is the
classic example of a specific genetic change leading to
malignant  transformation.  Mutations  in  the  Rb
tumor suppressor gene are observed in up to 70% of
soft tissue sarcomas.72,73 Whereas tumor suppressor
loss may be a common early event in some sarcomas,
in  others,  it  may  be  an  uncommon  late  event.
Neoplastic growth and metastatic potential may be
influenced by the abolition of tumor suppressor gene
regulatory  activity  over  cell  cycle  and  apoptotic
pathways. The presence of specific tumor suppressor
gene mutations may confer a molecular profile that
is predictive  of  tumor  behavior  and  clinical
response.2,69 Numerous examples of targeted ther-
apy for carcinoma focusing on restoration of tumor
suppressor gene function exist in the literature. These
reports  have  demonstrated the  potential  for  using
p53  pathways  to  reduce tumor burden at  primary
sites and limit metastases.169 Accordingly, restora-
tion of wild-type activity and reversal of the trans-
formed  phenotype  by  replacement  of  tumor
suppressor genes has been proposed as a therapeutic
strategy  for  sarcomas.70,71  This  is  believed  to  be
feasible since normal expression from only one of two
genes may be sufficient to maintain wild-type func-
tion. Other tumor suppressor targets associated with
various sarcomas are  currently under investigation
and include WT-1 (Wilm’s tumor 1),  MTS-1/p16
(multiple tumor suppressor 1) and RET (receptor of
tyrosine kinase).170
A particularly high incidence of Rb gene mutations
is reported in osteosarcoma, malignant fibrous histi-
ocytoma,  liposarcoma  and  mesenchymoma,74  and
these mutations strongly correlate with a poor overall
prognosis.75  Normally,  Rb  interacts  with  E2F  to
serve as a transcriptional repressor that inhibits cell
cycle  progression  and  controls  the  metabolic
response  to  DNA  damage.  Any  mutation  that
negatively alters Rb activity selects for increasingly
aggressive  clonal  populations of  transformed cells.
Therefore, it was reasonable to propose that reintro-
duction of a normal Rb gene would have therapeutic
benefit. Jiang et al. demonstrated that restoration of
Rb  protein  to  physiologically  relevant  levels  in
osteosarcoma cells resulted in a  significant growth
suppression  in vitro.76 Furthermore, transfection of
constitutively active Rb constructs demonstrated an
increased ability to arrest the cell cycle and inhibit
tumorigenesis.70
A second well-studied tumor suppressor is the p53
gene. Cytogenetic studies have revealed a significant
incidence of p53 alterations in many human cancers,
including  osteosarcoma,  Ewing’s  sarcoma,  malig-
nant fibrous histiocytoma, leiomyosarcoma, liposar-
coma  and  rhabdomyosarcoma.11,74,77,78  In
addition,  patients  with  the  familial  Li-Fraumeni
syndrome  consisting  of  sarcomas,  breast  cancer,32 R. J. Olsen et al.
lymphoma, leukemia, adrenal and brain tumors have
p53  abnormalities.79  At  the  molecular level,  wild-
type p53 is a transcription factor that mediates cell
cycle arrest, DNA repair and apoptosis.80 Mutation
is predictive of an increased tumor growth rate and
reduced  overall  survival.11  In  many  tumors,  mis-
sense mutations lead to the expression of an inactive
protein that  either fails  to  bind DNA  elements in
p53-regulated promoters or activate their transcrip-
tion. The ability of dominant-negative p53 to trans-
form primary sarcoma cells in vitro and form clonal
metastases in mice emphasizes its importance to the
neoplastic  process.81,82  Accordingly,  a  number of
novel  approaches  have  been  attempted  to  correct
abnormal p53 function. Recent experiments demon-
strated that p53 activity can be restored by the intra-
cellular expression of an scFv that binds its negative
regulatory domain.71 Similarly, reintroduction of the
wild-type  gene  to  cultured  leiomyosarcoma  cells
arrested the  cell cycle83  and resulted in a  marked
reduction  of  tumor  development  in  vivo.84
Comparable observations have also been recorded in
models of osteosarcoma,85 synovial sarcoma,86 and
alveolar  rhabdomyosarcoma.87  Furthermore,  p53
expression has been shown to sensitize sarcoma cells
to the cytotoxic effects of bleomycin, actinomycin D,
5-fluorouracil,  doxorubicin,  topotecan,  etoposide
and cisplatin.87 Adenoviral introduction of chimeric
tumor suppressor 1 (CTS1), a constitutively active
p53  derivative that  contains a  truncated inhibitory
domain  and  substituted  VP16  activation  domain,
has also been demonstrated to retard osteosarcoma
growth  in  vitro  and  inhibit  tumor  formation
in vivo.88
Abnormal regulation of p53 and Rb in sarcomas
may result from their interactions with proteins asso-
ciated  with  double  minutes.  Double  minutes  are
extrachromosomal  circular  DNA  fragments  often
recognized on chromosome spreads of tumor cells.
They may be present in large numbers and carry gene
sequences that are consequently amplified in human
cancer cells. The MDM2 (murine double minute 2)
proto-oncogene normally serves as a negative regula-
tor of p53 and Rb by binding a regulatory domain
that  prevents  their interaction with  the  CBP/p300
transcriptional adapter protein.91,93 MDM2 amplifi-
cation has been observed in liposarcoma, malignant
fibrous  histiocytoma,  alveolar  rhabdomyosarcoma
and osteosarcoma.89–92 Since the corresponding loss
of cell cycle control may be important to sarcomagen-
esis,93,94  its  restoration  may  represent  an  equally
appropriate therapeutic strategy. Antisense-mediated
inhibition of MDM2 in various soft tissue sarcoma
cells  restored  p53  activity,  decreased  clonogenic
survival  in  vitro  and  induced  a  dose-dependent
apoptotic  response  in  vivo.58,95  Chemotherapy,
particularly  adriamycin and  10-hydroxycamptothe-
cin, has additive or synergistic effects with antisense
compounds targeting MDM2.96
Inhibition of angiogenesis factors
A rich vascular supply is required to support the sub-
stantial  metabolic  demand  of  rapidly  proliferating
cells.97 Solid tumors have been shown to stimulate
angiogenesis by secreting factors that induce capillary
recruitment, microvessel migration and endothelial
expansion.98 Folkman has hypothesized that the abil-
ity of transformed cells to activate vessel formation is
fundamental  to  their  continued  maintenance  of
malignant behavior and any disruption in the supply
of vital nutrients or removal of waste products could
be detrimental to their potential for further metastatic
growth.99,100  Accordingly, many  laboratories  have
begun studying the concept of neovascular inhibition
as a therapeutic approach in sarcoma models.
The  most  frequent  target  of  anti-angiogenesis
strategies based on literature citations is VEGF (vas-
cular endothelial growth factor). VEGF,  a specific
mitogen for endothelial cells in vitro and an angio-
genic factor in vivo, is believed to serve as an essential
survival  factor  for  sarcoma.101  In  efforts  toward
achieving a therapeutic effect, several in vitro studies
have attempted to disrupt VEGF activity with inhib-
itory antibodies,102–104 small molecules105 and anti-
sense techniques,106,107 and many clinical trials are
now underway.108,109 Zhang et al. have recently dis-
covered that the p53 tumor suppressor gene exerts a
negative  regulatory  effect  on  VEGF  expression  in
several sarcoma cell types.86 Their studies demon-
strated that the angiogenic activity of wild-type syn-
ovial  sarcoma  cells  was  significantly  lower  in
comparison to tumors expressing a mutant gene, and
p53 restoration reduced the neovascularization and
microvessel  density  of  human  leiomyosarcoma
xenografts in SCID mice.86
The over-expression of COX2, an inducible iso-
form of cyclo-oxygenase, is believed to contribute to
sarcomagenesis by inducing the synthesis of growth
stimulatory prostaglandins. COX2 expression is also
associated  with  angiogenesis.  Two  recent  reports
independently  demonstrated  that  specific  COX2
inhibitors  significantly  decrease  tumor  growth  in
murine models of sarcoma.110,111 Inhibition was also
associated with a decreased level of tumor neovascu-
larization and an  enhanced cytotoxic  sensitivity  to
irradiation. 
Since angiogenesis relies upon the  expansion  of
endothelial cell populations, an alternative therapeu-
tic strategy is to directly target neovascular integrity.
Recently,  leiomyosarcoma  transplants  in  athymic
mice were effectively treated with an anti-endothelial
cell monoclonal antibody.112 131I conjugation of the
antibody further increased its inhibitory activity, evi-
denced by the presence of endothelial degeneration,
capillary  occlusion  and  tumor  necrosis.  In  1997,
Ixsys  Inc.  initiated  clinical  trials  with  Vitaxin,  a
humanized  MAb  that  recognizes  avb3  receptors.
These  receptors  are  preferentially  expressed  on
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tumor-associated blood flow without disturbing the
established vasculature of normal tissues.113 Phase I
dose escalation trials demonstrated that  no signifi-
cant toxicity was associated with Vitaxin treatment,
and two-thirds of the enrolled patients experienced
an objective clinical response.114 Phase II trials were
recently  initiated  at  the  M.D.  Anderson  Cancer
Center with 15 leiomyosarcoma patients who were
previously unresponsive to  conventional  treatment
regimens, and additional protocols with other sar-
coma types are planned.114 A phase I trial reported
clinical benefit in patients with advanced malignan-
cies  using  SU668,  a  novel  multi-receptor tyrosine
kinase inhibitor, that  acts on the VEGF (FLK-1),
PDGF (PDGFR) and FGF-1 (FGFR) receptors.3
Kaposi’s  sarcoma  is  an  unusual  multi-centric
vascular  tumor  associated  with  cellular  immune
deficiency and HIV infection. Essentially all patients
with  Kaposi’s  sarcoma  are  infected  with  human
herpes virus 8 (HHV8), suggesting a prominent role
in its pathogenesis.115,116 In infected host cells, the
virally encoded oncogenic G protein-coupled recep-
tor  (GPCR)  constitutively  promotes  VEGF-medi-
ated  angiogenesis and spindle cell proliferation.117
GPCR expression in fibroblasts was recently demon-
strated to result in cellular transformation, and trans-
fection  of  GPCR  was  shown  to  protect  human
umbilical vein endothelial cells (HUVECs) from the
apoptotic response induced by serum deprivation.118
Montaner and co-workers have suggested that GPCR
signaling serves as a survival pathway  for Kaposi’s
sarcoma  cells  and  have  begun  efforts  to  elucidate
potential mechanisms that  may  disrupt its tumori-
genic effect.118,119
Induction of apoptotic pathways
Neoplastic diseases are commonly characterized by
the  simultaneous presence of  uncontrolled cellular
proliferation  and  deficiencies  in  programmed  cell
death.120  Apoptosis  is  normally  regulated  by  a
complex  cascade  of  independent  and  interrelated
signaling pathways. Any amplification of inhibitory
genes or negative mutation of activator molecules can
disrupt  the  delicate  homeostatic  balance  between
mitotic division, effector function and cellular turno-
ver. The resulting loss of growth control has been
shown  to  significantly  influence  sarcoma  develop-
ment.37  Accordingly,  new  therapeutic  approaches
seeking to restore blocked apoptotic signals or exoge-
nously  induce  programmed  cell  death  are  being
investigated.
The CD99/MIC2 gene encodes an integral trans-
membrane glycoprotein that is commonly present on
mature lymphocytes and various undifferentiated cell
lineages.121,122 Although the molecular mechanism
of its function remains largely undefined, CD99 has
been  implicated  as  a  regulatory  factor  in  cellular
adhesion, proliferation, differentiation and apopto-
sis.123–125 A particularly high density of CD99 mole-
cules  is  observed  on  neuroectodermal  progenitor
cells,  and  its  immunohistochemical  detection  has
diagnostic  value  for  peripheral  neuroectodermal
tumors (PNET).126,127 The apparent restriction of
CD99 to PNET and its distinct association with apo-
ptotic pathways has led investigators to hypothesize
that surface molecule engagement may have thera-
peutic potential. Sohn et al. first reported that in vitro
cross-linking  of  CD99  by  the  agonistic  DN16
monoclonal antibody induced apoptosis in Ewing’s
sarcoma cells, but had no effect on neuroblastoma
cells.128  Scotlandi  et  al.  later  demonstrated  that
ligation with the 0662 MAb also resulted in a signifi-
cant  inhibition  of  growth.125  The  resulting  dose-
dependent  induction  of  apoptosis  was  absent  in
osteosarcoma  control  cells  devoid  of  extracellular
CD99. Furthermore, DN16 treatment reversed the
transformed phenotype of Ewing’s sarcoma in vivo
and potentiated the cytotoxic activity of doxorubicin
and  vincristine.  These  preliminary  studies  suggest
that CD99 engagement may translate into a highly
specific therapeutic mechanism for Ewing’s sarcoma.
Since relatively high levels of CD99 are observed in a
subset of malignant fibrous histiocytoma,129 synovial
sarcoma,130 chondrosarcoma131,132 and desmoplas-
tic small round cell tumor,133 the therapeutic poten-
tial of this technique may be extended to include a
wide range of neuroectodermal tumors expressing the
surface antigen.
The Fas/Fas-ligand system, also commonly termed
Apo1/Apo1-L or CD95/CD95-L, is recognized as a
major pathway  for the regulated induction of pro-
grammed cell death. Fas-mediated down-regulation
of  lymphocyte  populations  and  removal  of  auto-
reactive  cells  constitutes  an  important  element  to
immune system development.134,135  Recently, Fas
expression  in  soft  tissue  tumors  has  prompted
researchers to  explore  its  potential  as  a  molecular
target in sarcoma. Kontny et al. first reported that all
nine Ewing’s sarcoma cell lines studied expressed Fas
on their surface: three were readily killed by treat-
ment with exogenous ligand, and four others under-
went  cell  death  following  pre-incubation  with
interferon-g  (INF-g)  and  cycloheximide.136  Simi-
larly, in vitro ligation with an agonistic monoclonal
antibody  induced  a  dose-dependent  apoptotic
response in 10 osteosarcoma cell lines.137 The in vivo
sensitivity of alveolar rhabdomyosarcoma, leiomyosa-
rcoma and fibrosarcoma to these various Fas-medi-
ated  apoptotic  pathways  has  also  been
confirmed.138–140
The nuclear factor-kB (NF-kB) family of eukary-
otic  transcription  factors  mediate  expression  of
numerous  genes  having  biological  significance.141
These  include  a  variety  of  cytokines,  interferons,
growth factors and major histocompatibility complex
(MHC) molecules. Activation has also been shown to
confer protection against programmed cell death by34 R. J. Olsen et al.
suppressing pro-apoptotic pathways.142 In the inacti-
vated state, NF-kB dimerizes with I-kB, resulting in
its  cytoplasmic  retention. However,  upon stimula-
tion, the complex dissociates and liberated NF-kB
proteins enter the nucleus to interact with kB sites in
target gene promoters. Recently, in a fibrosarcoma
model,  NF-kB  inhibition  by  antisense  oligonucle-
otides  reduced  cellular  adhesion  to  extracellular
matrices and colony formation in soft agar.143 Simi-
larly,  transfection  of  a  constitutive  I-kB  construct
enhanced sarcoma cell susceptibility to tumor necro-
sis factor (TNF), daunorubicin and ionizing radia-
tion,96  and  a  dominant  negative  NF-kB  gene
reversed its inhibitory effect on apoptosis.144 Human
fibrosarcoma, leiomyosarcoma and malignant fibrous
histiocytoma (MFH) cells also underwent a signifi-
cant decrease in their viability as compared to null-
vector infected cells, and in vivo treatment reduced
tumor burden in SCID mice. 
The transcription factor E2F is known to serve as a
mediator of programmed cell death.145 Hunt et al.
reported that E2F activation in cultured leiomyosar-
coma cells efficiently reduced their viability.146 When
wild-type E2F was administered to established trans-
fectomas in nude mice, a marked inhibition of tumor
growth was observed, and a fraction of the animals
demonstrated complete regression.147,148
The  basic  fibroblast  growth  factor  (bFGF)  and
FGF-receptor (FGF-R) occupy a critical role in the
regulation of cell survival.149 This system is particu-
larly important during embryogenesis when cellular
proliferation, differentiation and apoptosis must be
tightly  controlled.  Sturla  et  al.  hypothesized  that
bFGF  and  FGF-R  may  contribute  to  the  initial
development and physiological behavior of pediatric
sarcoma.150 Ewing’s sarcoma cell lines that express
bFGF  and  FGF-R  were  treated  with  exogenous
ligand  resulting  in  a  dose-dependent  decrease  in
cellular  proliferation. Also,  anchorage-independent
growth of cells in soft agar and tumors in athymic
mice were inhibited. Histological analyses of biopsy
sections  demonstrated  a  reduced  cellularity  and
increased  frequency  of  apoptotic  nuclei  following
treatment. 
Tumor  necrosis  factor-a  (TNF-a)  is  a  positive
regulator of apoptosis. Although it mediates a death
process that occurs independently of the Fas-ligand
or NF-kB systems, their molecular pathways appear
to overlap significantly.142,151 TNF-a delivered by
thermosensitive liposomes has been demonstrated to
induce apoptosis in fibrosarcoma cells in vitro  and
implanted  tumors  in  vivo.152  Similarly,  treatment
with  TNF-related  apoptosis-inducing  ligand
(TRAIL) induced a  cytotoxic  response in Ewing’s
sarcoma.153 The results of a large clinical trial span-
ning nearly 5 years and involving 186 patients in eight
cancer centers were recently  reported.154  A major
response  was  observed  in  patients  with  either  an
inoperable high-grade primary or recurrent sarcoma
of the extremity. Treatment with TNF-a by isolated
limb perfusion and tumor resection resulted in a 29%
complete  response  rate  and  53%  partial  response
rate.153
Toxic genes
A  considerable  obstacle  to  developing  gene-based
therapies is the successful targeting  of every trans-
formed cell in the tumor. Suicide gene therapy, also
termed  gene-directed  enzyme  prodrug  therapy
(GDEPT), holds an advantage over other techniques
due to its ability to induce cytotoxicity in non-trans-
fected cells. This bystander phenomena increases the
effective  dose  of  administered agents  by  exposing
neighboring cells to toxic metabolites. Herpes sim-
plex virus thymidine kinase (HSV-tk) is one example
of the GDEPT system. When introduced into mam-
malian cells, tk efficiently phosphorylates the prodrug
forms of ganciclovir (GANC) and acyclovir (ACV)
into monophosphate nucleoside analogues that dis-
rupt DNA synthesis, inhibit cellular proliferation and
induce  cytotoxicity.  Early  clinical  experience  with
this  approach  in  brain  tumors  demonstrated  only
short-term benefit.155,156 Uchida et al. recently dem-
onstrated  that  administration  of  GANC  following
retroviral transfection caused the necrotic death of
human  pelvic  chondrosarcoma  cells  in  vitro  and
inhibited the growth of chondrosarcoma tumors in
nude mice.157 Similar results have also been reported
in  murine  models  of  fibrosarcoma,158,159
glioblastoma160 and osteosarcoma.161
The diphtheria toxin  A chain (DT-A)  has  been
studied as a potential suicide gene in sarcoma ther-
apy. DT-A catalyzes the ADP ribosylation of cellu-
lar  elongation  factor  2  (EF2),  resulting  in  the
inhibition  of  mRNA  translation  and  activation  of
apoptosis.  Massuda  et  al.  demonstrated  that  the
selective expression of DT-A by a PAX3 responsive
promoter  induced  cytotoxicity  in  PAX3/FKHR
expressing  alveolar  rhabdomyosarcoma  (ARMS)
cells.162 Tumors generated by murine sarcoma-180
cells  have  been  shown  to  be  eradicated by  DT-A
delivery.163,164  Similarly,  SN-38  (7-ethyl-10-
hydroxycamptothecin),  the  toxic  metabolite  of
CPT-11 (7-ethyl-10-(4-(1-piperidino)-1-piperdino)-
carbonyloxycamptothecin), inhibits DNA repair by
topoisomerase I and induces apoptosis following its
activation by carboxylesterases. In vitro studies have
demonstrated that human rhabdomyosarcoma cells
stably transfected with rabbit liver carboxylesterase
experience a significant increase in their sensitivity
to CPT-11.165,166
Discussion
The  molecular  strategies  for  sarcoma  therapy
reviewed  here  provide  both  concrete  examples  of
progress as well as promising opportunities for theMolecular approaches to sarcoma therapy 35
future. The essential observation is that clinical out-
comes have been improved using rational therapeutic
approaches  directly  targeting  molecular  pathways
associated  with  cancer.  Use  of  STI571  not  only
improves outcome in  CML,167  but  it  also  caused
regression in GI stromal tumor primary and meta-
static lesions.27 Future targets have been suggested
from the functional disruption of chimeric transcrip-
tion  factors  EWS/FLI1,  EWS/ATF1  and  PAX3/
FKHR  with  reduction of  tumor  cell  viability  and
induction of apoptosis in vitro.10,65 It is not yet clear
that molecular approaches can or should be the only
therapeutic modality, and in fact, the combination of
targeted therapy and conventional therapy including
radiation  and  chemotherapy  may  be  the  best
approach.  Greater  activity  has  been achieved with
gene-based approaches when  used in combination
with multiple agents with a variety of toxic effects on
cancer cells.168
Although  a  large  number  of  recent  scientific
studies and publications have focused on the role of
tumor-associated neovascularization in sarcomagen-
esis, immediate progress has not been forthcoming.
However, significant obstacles and limitations to the
use of anti-angiogenesis factors have been identified
and,  due  to  the  discovery  of  these  important
mediators,  substantial  advances  are  expected  to
ensue.100
As might  be  expected in an  emerging field, the
number  and  variety  of  problems  and  limitations
encountered is  great.  While  the  ability  to  disrupt
specific  pathways  using  molecular approaches  has
been clearly shown, the ability to deliver the poten-
tially  therapeutic  molecule  to  the  tumor  remains
problematic. Achieving intracellular accumulation of
the therapeutic molecule is an even greater challenge.
To  be  of  medicinal value,  the  administered agent
must  possess  two  fundamental  qualities.  First,  it
must demonstrate great specificity in its tumoricidal
activity. A drug that indiscriminately affects all cells
will have little additional value in comparison to the
currently  available  chemotherapeutic  or  radiation
options. Second, it must be packaged in a manner
that  allows  for delivery to  the  appropriate cellular
target. Since gene-based drugs interact with specific
molecular  pathways,  they  are  able  to  selectively
confer cytotoxicity at relatively low doses. However,
delivery mechanisms that effectively concentrate the
pharmacological  agent  in  tumor  cells  are  not  yet
available.  This  is  a  particular  concern  for  fusion
proteins with transcriptional activity confined to the
tumor  cell  nucleus.  Extracellular  epitopes  can  be
easily accessed through vascular channels; however,
the most attractive molecular targets under consider-
ation are nuclear proteins. The inability to efficiently
access  the  cellular  compartments  that  contain
chimeric transcription factors and tumor suppressor
genes  severely  limits  our  capacity  for  testing
molecular agents  in vivo.  Gene delivery represents
the greatest obstacle to successfully applying these
techniques in a clinical setting.171 Advances in the
drug delivery field should allow investigators to selec-
tively  transfect  sarcoma  cells  by  engineering  viral
vectors, immunoliposomes and high-affinity peptides
that recognize sarcoma-associated surface antigens.
Also,  the  continued  development  of  restricted
expression  systems  using  inducible  vectors  and
tissue-specific promoters will further enhance their
therapeutic  potential.  Furthermore,  vehicles  that
deliver these molecular agents to intracellular targets
must be developed. 
Recent experience from the monoclonal antibody
field may be useful in predicting how progress is likely
to be achieved in specific delivery of molecular thera-
peutics.  When  monoclonal antibodies  (MAb)  first
appeared, much excitement was generated regarding
their  potential  use  in  disease  treatment,  but  few
successes  occurred  beyond  their  use  to  deliver
targeted radioactivity.172 Now monoclonal antibod-
ies  that  bind  extracellular  receptors  have  greatly
impacted the treatment and survival of breast cancer,
colon  cancer,  lymphoma  and  leukemia.173  The
potential for using the exquisite specificity of anti-
bodies for selected epitopes has now been exploited
to  selectively  kill  diseased cells  without  disturbing
healthy counterparts.174 The clinical efficacy of Rit-
uximab (anti-CD20)  in non-Hodgkin’s lymphoma,
Campath-1H  (anti-CD52)  in  chronic  lymphocytic
leukemia, Herceptin (anti-her2/neu) in breast cancer
and  Centuximab  (anti-EGFR)  in  colorectal  carci-
noma has renewed interest in their potential applica-
tion to soft  tissue sarcoma.175–178 One of  the key
advances in genetic engineering that made these suc-
cesses possible was the ability to produce ‘human-
ized’  versions  of  murine  monoclonal  MAbs  that
minimize  the  immune  response  against  rodent
proteins due to species incompatibility. Recently, an
anti-CD33  antibody  (Gemtozumab  ozogamicin)
armed  with  a  chemotherapeutic  agent  has  been
approved for acute myelogenous leukemia.179 The
antibody–drug  combination  is  internalized  and
cleaved to deliver an intracellular dose of the active
product.  Addition  of  radioactive  molecules  to  an
antibody recognizing surface antigens has achieved
killing  of  targeted  cells  as  well  as  bystander  cells
without the surface receptor.180,181
Although MAbs provide an excellent tool for the
engagement of surface antigens and soluble proteins,
a  majority  of  the  nuclear  targets  identified  for
sarcoma intervention remain inaccessible since they
are not naturally internalized. Recombinant antibody
technology can circumvent this restriction by gener-
ating  cloned MAb  derivatives  termed single  chain
variable  fragments  (scFv).182  ScFv  molecules  are
composed  of  an  antibody  heavy  and  light  chain
variable  domain  (VH  and  VL)  joined  by  a  short
peptide linker. Since its sequence is encoded by a
single gene, the scFv cDNA can be introduced into36 R. J. Olsen et al.
cells and expressed as  a  functional protein having
antigen-binding properties identical  to  its  parental
immunoglobulin. Also, the comparatively small size
of scFv renders them relatively non-immunogenic to
the  host  system  and  provides  an  advantageous
pharmacological profile.183,184 Previous studies have
demonstrated that p53 tumor suppressor activity was
restored by expression of an agonistic scFv targeting
its regulatory domain,71 and transcriptional activity
of the EWS/ATF1 fusion protein was disrupted by an
inhibitory  fragment  recognizing  its  DNA-binding
domain.31  The recombinant nature  of  scFv  mole-
cules also allows for their use in directing drug trans-
port  by  incorporation  into  immuno-liposomes  or
viral coat proteins, and their activity can be enhanced
by addition of leader sequences directing subcellular
localization,  high-valency  multimer  formation  or
increased tissue uptake and cellular retention.185–187
Furthermore, when combined with structural studies
and molecular modeling simulations, the fine speci-
ficity of antibody combining sites can be rationally
engineered into bioactive protein loops or peptidomi-
metic compounds that display enhanced therapeutic
effects.
Based on successes described here, the most fruit-
ful targets for molecular intervention and additional
investigation may be the post-translational modifica-
tions that potentially enhance chimeric transcription
factor activity. In addition, targeting strategies should
be  investigated  for  other  translocation-generated
fusion proteins such as SYT/SSX in synovial sarcoma
and TLS/CHOP in myxoid liposarcoma.10,65 Exper-
iments must determine whether the cytotoxic effects
of inhibiting transcription factor binding are due to a
reduced expression of growth stimulating genes or a
downstream release from apoptotic inhibition. These
concerted efforts will continue to expand our under-
standing of  molecular sarcomagenesis and identify
many  new  mediators  and  signaling  pathways  of
potential importance. With this knowledge, we will
be able to refine our current approaches and develop
novel  strategies  that  specifically  counteract  the
neoplastic program at the genetic level. 
Perhaps the greatest obstacle to overcome is the
difficulty in obtaining sufficient resources to further
develop therapies for tumor types that constitute less
than 1% of all human cancers. However, the dispro-
portionate number of cases that occur in children and
the poor prognosis both argue for the necessity of
continued  effort.  With  adequate  support,  it  is
expected that many of the agents discussed here will
become available  for  clinical  evaluation,  and  their
ability to improve patient outcomes will be critically
evaluated. There remains significant concern that the
true  therapeutic  potential  of  molecular techniques
will not be immediately realized because of the way
clinical trials are currently evaluated. The introduc-
tion of molecular therapy will require that response
criteria applied to traditional cytoreductive chemo-
therapy strategies be reconsidered and significantly
modified. Current measures of  tumor response to
therapy include complete remission (CR) or partial
remission  (PR),  whereas  stable  disease  (SD)  is
usually  considered  a  treatment  failure.  However,
improved performance status and stable disease may
be  an  important  measure  of  treatment  outcome.
Tumor response to molecular therapies should also
be monitored with more sophisticated monitors of
biological activity, such as real time PET scanning. In
the future, cancer treatment will become even more
complex and include multimodality therapies with
chemotherapy,  surgery,  radiation  and  combined
administration of various targeted antibodies. There-
fore a continued emphasis is needed upon in vitro
studies and animal models to further our understand-
ing  of  sarcomagenesis and refine our use of  these
emerging technologies.
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